Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
PCSA Processa Pharmaceuticals, Inc. daily Stock Chart
PCSA [NASD]
Processa Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.07 Insider Own16.00% Shs Outstand5.59M Perf Week22.61%
Market Cap50.82M Forward P/E- EPS next Y-0.51 Insider Trans2.13% Shs Float4.24M Perf Month35.25%
Income-6.00M PEG- EPS next Q-0.55 Inst Own10.65% Short Float0.15% Perf Quarter-33.65%
Sales- P/S- EPS this Y0.90% Inst Trans- Short Ratio0.16 Perf Half Y-66.43%
Book/sh0.99 P/B5.70 EPS next Y19.00% ROA-58.90% Target Price- Perf Year-76.30%
Cash/sh0.03 P/C169.39 EPS next 5Y- ROE-87.10% 52W Range3.40 - 18.00 Perf YTD-68.67%
Dividend- P/FCF- EPS past 5Y29.80% ROI- 52W High-68.67% Beta-0.52
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low65.88% ATR0.30
Employees13 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)57.76 Volatility10.68% 5.52%
OptionableNo Debt/Eq0.31 EPS Q/Q-252.40% Profit Margin- Rel Volume0.24 Prev Close5.40
ShortableYes LT Debt/Eq0.02 EarningsNov 12 AMC Payout- Avg Volume39.16K Price5.64
Recom2.00 SMA2026.50% SMA501.89% SMA200-58.63% Volume9,211 Change4.44%
Nov-16-20 12:48PM  
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire +5.39%
Nov-12-20 05:02PM  
Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update
GlobeNewswire
Nov-05-20 09:15AM  
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
GlobeNewswire
Nov-03-20 09:20AM  
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET
GlobeNewswire
Oct-13-20 09:30AM  
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
GlobeNewswire
Oct-07-20 09:25AM  
Patrick Lin Is The Co-Founder of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) And They Just Picked Up 8.5% More Shares
Simply Wall St. +7.84%
Oct-06-20 04:05PM  
Processa Pharmaceuticals Closes $19.2 Million Public Offering
GlobeNewswire
Oct-02-20 06:00AM  
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
GlobeNewswire -35.25%
Aug-27-20 09:30AM  
PROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMORS
GlobeNewswire +10.00%
Aug-20-20 09:30AM  
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS
GlobeNewswire
Jun-01-20 09:30AM  
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUG
GlobeNewswire
Mar-30-20 04:00PM  
PROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING
GlobeNewswire
Mar-17-20 09:30AM  
PROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA
GlobeNewswire
Mar-05-20 09:30AM  
PROCESSA PHARMACEUTICALS ANNOUNCES FORMATION OF ITS MEDICAL AND SCIENTIFIC ADVISORY BOARD
GlobeNewswire
Feb-25-20 09:30AM  
PROCESSA PHARMACEUTICALS PROVIDES SHAREHOLDER UPDATE
GlobeNewswire
Feb-13-20 09:30AM  
PROCESSA PHARMACEUTICALS APPOINTS GERALDINE PANNU AS AN INDEPENDENT DIRECTOR TO THE BOARD OF DIRECTORS
GlobeNewswire
Dec-20-19 04:10PM  
PROCESSA PHARMACEUTICALS ANNOUNCES 1 FOR 7 REVERSE STOCK SPLIT OF ITS COMMON STOCK
GlobeNewswire
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was founded in 2015 and is based in Hanover, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BESSER JAMES E10% OwnerOct 02Buy4.0430,000121,200405,000Oct 13 06:33 PM
open in yahoo | open in reuters | open in google
affiliate | advertise | contact | privacy | help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.